Eagle Laboratories Profile
Key Indicators
- Authorised Capital ₹ 0.50 M
- Paid Up Capital ₹ 0.39 M
- Company Age 69 Year, 1 Month
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 7.27 M
- Revenue Growth -6.29%
- Profit Growth 975.14%
- Ebitda 5.38%
- Net Worth 1.27%
- Total Assets 1.31%
About Eagle Laboratories
Eagle Laboratories Pvt Ltd (ELPL) was founded in India on 31 December 1955 and has a glorious history of 69 years and one month.Its registered office is in Kolkata, West Bengal, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 0.50 M and a paid-up capital of Rs 0.39 M.
The company currently has active open charges totaling ₹7.27 M.
Jiban Bose, Nandini Bose, and Adhip Sarkar serve as directors at the Company.
Company Details
- Location
Kolkata, West Bengal, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
-
- Social Media -
Corporate Identity Details
- CIN/LLPIN
U24232WB1955PTC022842
- Company No.
022842
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
31 Dec 1955
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Kolkata
Industry
Who are the key members and board of directors at Eagle Laboratories?
Board Members (3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Jiban Bose  | Director | 14-Jan-2011 | Current |
| Nandini Bose | Director | 21-Nov-1990 | Current |
| Adhip Sarkar | Director | 12-Jun-1981 | Current |
Financial Performance of Eagle Laboratories.
Eagle Laboratories Pvt Ltd, for the financial year ended 2022, experienced Minor drop in revenue, with a 6.29% decrease. The company also saw a substantial improvement in profitability, with a 975.14% increase in profit. The company's net worth moved up by a moderate rise of 1.27%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Eagle Laboratories?
In 2021, Eagle Laboratories had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
₹7.27 M
₹0
Charges Breakdown by Lending Institutions
- State Bank Of India : 0.73 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 28 Dec 1993 | State Bank Of India | ₹7.27 M | Open |
How Many Employees Work at Eagle Laboratories?
Eagle Laboratories has a workforce of 2 employees as of Apr 10, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Eagle Laboratories, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Eagle Laboratories's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.